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A B S T R A C T
A systematic approach was developed to investigate the stability of gentamicin sulfate (GS) and GS/poly (lactic-
co-glycolic acid) (PLGA) coatings on hydroxyapatite surfaces. The inﬂuence of environmental factors (light,
humidity, oxidation and heat) upon degradation of the drug in the coatings was investigated using liquid
chromatography with evaporative light scattering detection and mass spectrometry. GS coated rods were found
to be stable across the range of environments assessed, with only an oxidizing atmosphere resulting in
signiﬁcant changes to the gentamicin composition. In contrast, rods coated with GS/PLGA were more sensitive
to storage conditions with compositional changes being detected after storage at 60 °C, 75% relative humidity or
exposure to light. The eﬀect of γ-irradiation on the coated rods was also investigated and found to have no
signiﬁcant eﬀect. Finally, liquid chromatography–mass spectrometry analysis revealed that known gentamines
C1, C1a and C2 were the major degradants formed. Forced degradation of gentamicin coatings did not produce
any unexpected degradants or impurities.
1. Introduction
Over the past decade, scientists have been working at the frontier
between materials science and pharmaceutics to develop new ortho-
pedic devices with functionalized antibacterial coatings [1–5]. This
interest has been driven by the ongoing problem of periprosthetic joint
infection in 0.3%–9% of patients following total replacement of the hip,
knee or ankle [6]. Patients with implanted devices are particularly
susceptible to infection due to compromised host defense at the
implant/tissue interface [1,7]. Furthermore, implant adherent bacteria
typically exist as a bioﬁlm, which protects the former from the host
immune system and antibacterial agents [8,9]. Treatment of such
bacterial bioﬁlm usually requires surgical removal of the implant,
followed by replacement in one or two stages depending on the nature
of the infection [6]. Therefore, it becomes necessary to explore
alternative procedures for preventing implant associated infections in
the ﬁrst instance.
One such method is the application of antimicrobial coatings to the
biomedical implant. Such coatings can disrupt the adhesion of bacteria
to the implant surface, and bolster the host's immune system in the
interface region between implant and tissue [1]. Gentamicin is the
antibiotic most widely exploited in antibiotic coatings of implants due
to its relatively broad antibacterial spectrum and thermal stability
[1,3,4]. Other antimicrobials which have also been used in implant
coatings include cephalothin [4], carbenicillin [4], amoxicillin [4],
cefamandol [4], tobramycin [4], vancomycin [4,10,11], chlorhexidine
[12], chloroxylenol [13], silver [14], copper [15], and zinc [16].
Gentamicin is an aminoglycoside antibiotic consisting of four major
components (C1, C1a, C2, C2a) and a minor component C2b which are
produced by fermentation of Micromonospora purpurea or
Micromonospora echinospora (Fig. 1) [17,18]. The ratio of the
individual congeners is dependent on the origin of the sample and
accepted limits to these ratios are speciﬁed in the United States and
European Pharmacopoeias [19,20]. During the fermentation process a
number of other minor impurities (e.g. sisomicin, and JI-20B) and
degradation products (2-deoxystreptamine, and garamine) can also be
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formed (Fig. 1) [21]. Bulk gentamicin mixtures as an active pharma-
ceutical ingredient (API) are typically characterized by high perfor-
mance liquid chromatography (HPLC) with the detection of the major
components facilitated by UV detection of their ortho-phthaldehyde
derivatives [22,23], pulsed electrochemical detection [24–26], charged
aerosol detection [27] or evaporative light scattering detection (ELSD)
[24,28,29]. Liquid chromatography–mass spectrometry (LC–MS) has
also been employed to establish impurity proﬁles of gentamicin
mixtures [30–32].
A particular formulation has been developed and investigated in
previous studies [33–36], with the objective of clinical use in cement-
less hip prostheses. In vitro testing of grit blasted and porous titanium
coupons coated with 1.0 mg gentamicin per cm2 and a poly(lactic-co-
glycolic acid) (PLGA) overcoat has shown them to be as eﬃcacious as a
commercially available antibiotic-loaded bone cement for preventing
infection [33,34]. Subsequent in vivo studies have demonstrated both
the antibacterial eﬃcacy of this coating formulation and that it
supports the integration of bone tissue into the implant surface through
its relatively fast in vivo dissolution [35,36]. As part of this convergent
technology development it is necessary to investigate the stability of the
active drug coating under common sterilization and storage conditions
used for medical implants.
The degradation of gentamicin as a pure API or in solution is well
established [37]. However, alternative degradation pathways might be
possible on interaction of gentamicin with the surface of a medical
device. Friess and Schlapp [38] have reported the short-term stability
of gentamicin loaded PLGA microparticles and collagen/PLGA compo-
sites sterilized by ethylene oxide treatment as well as β- and γ-
irradiation. Ethylene oxide sterilization resulted in chemical changes
to the gentamicin drug substance, while storage of irradiated samples
at 40 °C and 75% relative humidity (RH) resulted in degradation of the
polymer support. To our knowledge there have been no reported
studies for the degradative behavior of gentamicin on titanium or
hydroxyapatite device surfaces.
The goal of this study was to evaluate the degradation pathways of
gentamicin coatings on hydroxyapatite implant devices under common
storage conditions. While gentamicin is known to be a heat stable
antibiotic when stored under standard conditions as an API, incorpora-
tion on the surface of a material may lead to diﬀerent stability levels
and degradation pathways. Accordingly, a range of temperatures were
studied to establish the thermal stability/lability of gentamicin on
surfaces. The impact of sterilization by γ-irradiation of the drug/device
combination products was also investigated. To facilitate these studies
a simple yet robust method was developed for the extraction of the drug
coating from the combination devices. Extracts of the drug coating
were analyzed by HPLC with ELSD to determine the ratio of the major
components in the gentamicin coating. The extracts were also analyzed
for common gentamicin degradants and impurities using LC–MS. In
the present study gentamicin sulfate (GS) coated hydroxyapatite rods
were used as a convenient model system for larger implant devices.
2. Experimental
2.1. Reagents and chemicals
GS was obtained from Lek (Lubljana, Slovenia). HPLC grade water,
acetonitrile and methanol were from Sigma-Aldrich (St Louis, MO,
USA). Triﬂuoroacetic acid (99%) (TFA) was from Sigma-Aldrich.
Nitrogen gas (purity: 99.995%) was supplied by BOC (Guildford,
UK). GS and GS/PLGA coated hydroxyapatite rods were obtained from
DePuy Synthes (Cork, Ireland), produced via a process equivalent to
previous published work on this coating [35,36]. The rods were
received in sealed aluminum foil pouch packaging.
2.2. Instrumentation and chromatographic conditions
2.2.1. LC–ELSD chromatographic conditions
The LC–ELSD apparatus consisted of an 1120 Compact LC system,
a 385-ELSD evaporative light scattering detector and ChemStation
B.04.03 software (all from Agilent Technologies, Santa Clara, CA, USA)
for data acquisition. Nitrogen (purity 99.995%) was used as the
evaporation gas at a ﬂow rate of 1.6 L/min. ELSD was operated with
the nebulizer and evaporator temperatures of 40 °C.
The LC–ELSD method was adapted from those previously reported
by Agilent Technologies [39] and Clarot et al. [28]. An Atlantis T3 C18
column (150 mm×4.6 mm, 5 µm, Waters, Milford, MA, USA), main-
tained at 25 °C in the 1120 Compact LC column heater, was used for
chromatography. The mobile phase was an isocratic mixture of an
aqueous solution of triﬂuoroacetic acid (0.2 mol/L, pH 1.5) and
methanol in a ratio of 92:8 (v/v). The mobile phase ﬂow rate was
Fig. 1. Structure of gentamicin congeners as well as its common impurities and degradants.
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1 mL/min.
All GS standard solutions were prepared in water. The injection
volume was 10 µL. GS standards were prepared at concentrations of
0.1–1 mg/mL and used to calibrate the detector response.
2.2.2. LC–MS chromatographic conditions
The LC–MS apparatus consisted of a 2695 Separations Module, a
2996 Photodiode Array Detector, an LCT Premier KD160 mass
spectrometer and MassLynx 4.1 software (all from Waters, Milford,
MA, USA) for data acquisition. Chromatographic column and condi-
tions employed for LC–MS studies were the same as given above for the
LC–ELSD data generation.
2.2.3. 1H nuclear magnetic resonance (NMR) spectroscopy analysis
1H NMR spectra were recorded in D2O on a Bruker Avance NMR
spectrometer operating at 600 MHz at room temperature (20 °C).
2.3. Isolation of gentamicin sulfate components
Pure samples of the major components of GS were isolated using
the LC–ELSD. An initial analysis of GS performed using the LC–ELSD
method reported above with an injection volume of 50 µL, provided
retention times for the C1a, C2, C2a, and C1 components. The ELSD
detector was subsequently disconnected and fractions of the eluent
were collected from the detector inlet at the previously determined
time intervals (C1a 5.0–6.0 min, C2 6.9–7.9 min, C2a 9.0–9.9 min, C1
11.0–12.0 min). Fifteen injections of a 0.25 mg/mL GS solution were
processed. Evaporation to dryness of the pooled fractions provided
samples of gentamicin C1a, C2, C2a, and C1 in good purity, as
determined by LC–ELSD, NMR spectroscopy and high resolution mass
spectrometry (HRMS).
2.4. Chemical stability
The stability of GS coated rods under a range of storage conditions
was studied over 30 days. The variations of storage conditions
investigated are shown in Table 1.
(1) Thermal: samples were stored at a low temperature (4 °C) or high
temperature (60 °C) in sealed vessels to establish the thermal
stability of the gentamicin on the rods.
(2) Sensitivity to oxidation: oxidizing storage conditions were simu-
lated by suspension of samples over a solution of 30% (m/m)
hydrogen peroxide, while in contrast to simulate storage in a non-
oxidizing environment samples were stored under nitrogen gas at
20 °C. Both were shielded from light.
(3) Humidity: humidity variations were simulated by sample storage
at low humidity (20% RH, suspension over saturated potassium
acetate solution) or high humidity (75% RH, suspension over
saturated sodium chloride solution) in sealed containers at 20 °C
[40].
(4) Light: low light storage conditions were simulated by storage of the
samples in open foil pouches at 20 °C while high light conditions
were achieved by storage of the samples under a ﬂuorescent light.
(5) Irradiation: GS coated rods were subjected to sterilization by γ-
irradiation (carried out by DePuy Synthes) at low (25 kGy) and
high (40 kGy) doses [41].
On completion of the storage period, the organic material was
extracted from the coated hydroxyapatite rods by immersion in a
solution of TFA/acetonitrile/water (0.3/3/97, v/v/v) [200 mL]. The
vessels were sonicated for 1 h at room temperature. The resulting
solution was ﬁltered and evaporated to dryness. Portions of the
residues (10 mg) were dissolved in water (1 mL) and analyzed by
LC–ELSD and LC–MS. LC–ELSD results were recorded as % (m/m)
based on the assumption that structurally similar gentamicin con-
geners have the same ELSD response factors [42] (Table S1). LC–MS
results were recorded as peak area ratios relative to the gentamicin C1
peak area.
As summarized in Table 1, the samples of GS coated rods were
originally received in sealed foil pouches under a protective atmo-
sphere. For the light, humidity and oxidation stability tests the pouches
were opened to enable exposure of the coating to the appropriate test
conditions. Accordingly, exposure to open atmosphere in addition to
the speciﬁc stability tests was incorporated in the study.
3. Results and discussion
3.1. Analysis of bulk gentamicin sulfate
The European Pharmacopoeia deﬁnes acceptable limits for the
composition of GS (Table 2) [19]. The bulk GS used for preparing
coated devices in this study was examined using LC–ELSD to deter-
mine its composition before the application of the device coating
(Fig. 2). The composition of the bulk material was also determined
separately using 1H NMR spectroscopy. The anomeric protons of the
four gentamicin constituents could be separately assigned by resolution
Table 1.
Environments for chemical stability tests.
Environment Conditions
Low light Rods were stored in the foil pouch packaging with a small opening to allow for air penetration at 20 °C in the dark.
High light Rods were removed from the foil pouch and placed under a fluorescent lamp.
Low temperature Rods were stored in the sealed foil pouch packaging and refrigerated at 4 °C.
High temperature Rods were stored in the sealed foil pouch packaging in an oven at 60 °C.
Low humidity Rods were stored in the foil pouch packaging, with a small opening to allow for air penetration, and suspended in a sealed container containing a saturated
potassium acetate solution at 20 °C (20% RH).
High humidity Rods were stored in the foil pouch packaging, with a small opening to allow for air penetration, and suspended in a sealed container containing a saturated
sodium chloride solution at 20 °C (75% RH).
Low oxidation Rods were stored in opened foil pouches, shielded from light, at 20 °C, under a nitrogen atmosphere.
High oxidation Rods were stored in opened foil pouches, shielded from light, at 20 °C, suspended over a solution of 30% hydrogen peroxide.
Low irradiation Rods in their sealed foil packaging were subjected to a standard gamma dose (25 kGy)
High irradiation Rods in their sealed foil packaging were subjected to a high gamma dose (40 kGy).
Table 2.
Composition (m/m) of bulk gentamicin sulfate determined by LC–ELSD and 1H NMR
spectroscopy.
Methods Components (%, m/m)
C1 C1a C2 (C2+C2a+C2b)
EU Pharm. 25–45 10–30 35–55
LC–ELSD 38 11 51
1H NMR 37 14 49
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of the signal at 5.9 ppm. Integration of this signal revealed the ratio of
gentamicin components [43]. The LC–ELSD and 1H NMR spectro-
scopy determinations for our GS were in agreement, and were within
the European Pharmacopoeia limits. This also veriﬁed that the major
components of GS displayed an equivalent response in ELSD detection.
3.2. Isolation of gentamicin sulfate components
The individual gentamicin C1, C1a, C2 and C2a congeners were
isolated using HPLC to provide pure standards for use in our LC–ELSD
and LC–MS analyses (Fig. S1).
3.3. Chemical analysis of gentamicin coated hydroxyapatite devices
In order to study the gentamicin coating on medical devices it was
desirable to have a method for the extraction of the coating into a
solution. The extraction of the gentamicin coating could be eﬀectively
achieved by sonication of the coated rods in a solution of triﬂuoroacetic
acid, acetonitrile and water in a ratio of 0.3:3:97 (v/v/v) at room
temperature. Subsequent analysis of the concentrated extract by LC–
ELSD revealed a gentamicin composition of 41% C1, 8% C1a, 43% C2
and 8% C2a. While this composition was marginally outside of the
European Pharmacopoeia speciﬁcation for gentamicin drug product, it
was considered suﬃciently close to that of the bulk GS to indicate that
Fig. 2. LC–ELSD chromatogram of gentamicin sulfate [39].
Fig. 3. The eﬀect of 30-day storage conditions on the composition of the GS coating determined by HPLC–ELSD. Control: control extraction, GR: GS coated rod, GPR: GS and PLGA
coated rod, LT: stored at 4 °C, HT: stored at 60 °C, LH: stored under 20% RH, HH: stored under 75% RH, LL: stored in dark, HL: stored under light, LO: stored under nitrogen
atmosphere, HO: stored over 30% H2O2.
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the extraction method was eﬃcient and non-destructive.
3.4. Stability of the gentamicin sulfate coating studied by LC–ELSD
One of the core objectives of this study was to assess the chemical
stability of gentamicin coatings on hydroxyapatite devices and deter-
mine if there were environmental factors impacting on shelf life. For
the purpose of this pilot study, GS coated hydroxyapatite rods supplied
by DePuy Synthes were subjected to a 30 day forced degradation study
to determine the inﬂuence of temperature, humidity, atmospheric
oxidation and light exposure. For these stability studies, it was
important that the sealed foil pouches in which the rods were supplied
were opened for the stability tests (other than thermal and irradiation
studies) to evaluate eﬀect of exposure to stress factor as compared to
the packaged products. Also the hydroxyapatite rods coated with both
GS and PLGA were subjected to the same forced degradation studies.
3.4.1. Thermal stability
Gentamicin is well noted for being a heat stable antibiotic, retaining
its activity even after autoclaving [44,45]. It is this stability under
autoclave conditions that makes it a favored antibiotic for use in
antimicrobial coated devices [1,3,4]. In the present study, storage of
the rods in sealed pouches at temperatures of 4 °C and 60 °C had no
noticeable eﬀect on the chemical composition of the coating consisting
of just GS (Fig. 3A). When the rods coated with both GS and PLGA
were stored at 60 °C in sealed pouches, the resulting gentamicin
composition showed a small but signiﬁcant reduction in the level of
C2 (43% down to 36%) relative to the other congeners. This result
indicates that the thermal stability of GS may be reduced in coatings
containing PLGA.
3.4.2. Stability to humidity
The International Pharmacopoeia describes GS as being hygro-
scopic and susceptible to gradual degradation on exposure to a humid
atmosphere with the decomposition being faster at higher tempera-
tures [46]. Storage of the GS and GS/PLGA coated rods in the opened
foil packaging at a low RH of 20% resulted in no change to the congener
ratios of gentamicin in the coating. However, storage of both types of
coated rods at 75% RH resulted in small decreases in the level of
gentamicin C2 relative to the other congeners (Fig. 3B). The presence of
PLGA in the coating had little eﬀect on the stability of gentamicin
under high humidity. The changes observed in this study were
relatively small but it should be noted that the high RH test was
conducted at room temperature over a limited period of 30 days. A
combination of high RH and high temperature might be expected to
exert more of an eﬀect on the gentamicin coating over longer time
periods.
3.4.3. Stability to atmospheric oxidation
Oxidative processes are known to occur in the biosynthetic inter-
conversion of gentamicin and its several known impurities such as JI-
20B [47]. It was therefore expected that an oxidizing atmosphere might
lead to degradation of gentamicin. Also the amino and hydroxyl
functional groups in GS are reported as being susceptible to chemical
oxidation [37]. Furthermore, the glycoside linkages of several amino-
glycosides are known to be cleaved under oxidizing conditions [48]. In
the present study, no changes were observed in the composition of GS
and GS/PLGA coatings stored in open pouches under an inert nitrogen
atmosphere. Storage of the coated rods in open pouches in an oxidizing
atmosphere, over a solution of hydrogen peroxide (30%, m/m),
resulted in measurable changes to the gentamicin composition of GS
and GS/PLGA coatings. Small increases in the relative level of
Fig. 4. The eﬀect of 30-day storage conditions on relative level of common impurities in the GS coating determined by LC–MS. Control: control extraction, GR: GS coated rod, GPR: GS
and PLGA coated rod, LT: stored at 4 °C, HT: stored at 60 °C, LH: stored under 20% RH, HH: stored under 75% RH, LL: stored in dark, HL: stored under light, LO: stored under
nitrogen atmosphere, HO: stored over 30% H2O2.
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gentamicin C2 were observed, while gentamicin C1 was noticeably
decreased from 41% to 34% in both the GS and GS/PLGA coatings
(Fig. 3C).
3.4.4. Stability to light exposure
Hydroxyapatite rods coated with either GS or GS/PLGA were stored
in the dark and under a ﬂuorescent light for 30 days in an open
atmosphere in both cases. After this period of storage, no changes were
observed in the gentamicin composition of rods stored in the dark
(Fig. 3D). The GS coated rod also appeared to be stable to storage
under the ﬂuorescent lamp with no measurable change in the
gentamicin congener ratios measured by LC–ELSD, while the GS/
PLGA coated rod did undergo changes when stored under the lamp.
Under the high light exposure conditions, the C2 level was signiﬁcantly
reduced to 31% in the GS/PLGA coating. This indicated that even
though gentamicin appeared to be stable to light, the presence of other
components (such as PLGA) in antimicrobial coatings could lead to
signiﬁcant photodegradation.
3.5. Analysis of common impurities by LC–MS
The extracts obtained from the stability studies were also subjected
to LC–MS analysis to screen for common gentamicin impurities and
degradants. The characteristic ions for many of these gentamicin
impurities have been previously reported [30–32]. Total ion count
chromatograms showed the presence of the ﬁve gentamicin C compo-
nents. The presence of key degradants and impurities in the extracts
were determined by ion extraction method.
Garamine fragmentation ions were detected in all samples as
multiple peaks due to fragmentation of the major gentamicin con-
geners inside the mass spectrometer. However, m/z 322 peak was also
observed at 2.59 min, which was not observed with any heavier ions,
suggesting that this peak represented garamine degradants formed
prior to LC–MS analysis. Measurement of this peak in the extracts
revealed garamine levels of 1%–6% with the maximum level being
observed in samples stored under a highly oxidizing atmosphere (5%–
6%). No garamine was detected in the control extract taken from a rod
not subjected to forced degradation studies.
The extracts were expected to contain gentamines in signiﬁcant
levels if severe degradation of the corresponding gentamicin C compo-
nents had occurred under the tested environmental conditions.
Gentamine C1, arising from degradation of gentamicin C1, was
observed at levels of 2%–5% in most extracts. However, there was
noticeably more gentamine C1 (19%) observed in samples subjected to
highly oxidizing conditions. Conditions of low humidity also led to an
increase in gentamine C1 levels (7%–9%). The C1a and C2 gentamines
showed a similar increase in levels for samples that experienced a
highly oxidizing atmosphere.
G-418, sisomicin and JI-20B are common in batches of GS and are
related to gentamicin through biotransformative processes [47].
Sisomicin and the antibiotics JI-20B and G-418 were observed at
levels below 1% in all the samples (Fig. 4).
The storage conditions employed in this study generally had little
eﬀect on the composition and degradation of the gentamicin coated
rods; the exception being the highly oxidizing environment (Fig. 4).
After 30 days the only major degradants observed were gentamines
arising from the cleavage of the A-ring from the B-C gentamicin ring
system. All the LC–MS peaks observed in this study could be attributed
to previously reported gentamicin impurities [30–32]. Thus, there was
no evidence that gentamicin underwent substantive unique degrada-
tion pathways when applied as a device coating at readily detectable
levels .
3.6. Stability to γ-irradiation
γ-Irradiation is a common method for the sterilization of medical
devices and has previously been employed for gentamicin containing
PLGA composite particles [38]. Friess and Schlapp have reported that
free radicals, detected by electron spin resonance spectroscopy, were
formed in gentamicin loaded particles sterilized by exposure to
28.9 kGy of γ-irradiation. These free radicals did not persist beyond
four weeks in gentamicin and had no detectable eﬀect on the 1H NMR
spectrum of gentamicin. [38] In our study, we employed 25 kGy and
40 kGy dosages of γ-irradiation to sterilize GS and GS/PLGA coated
hydroxyapatite rods. LC–ELSD and LC–MS analysis of extracts after
low and high dose γ-irradiation did not display any signiﬁcant changes
compared to extracts from unsterilized rods (Fig. 5). These results
conﬁrmed that γ-irradiation is a suitable sterilization method for use
with gentamicin coated medical implants.
As stated, LC–ELSD analysis revealed that the change in composi-
tion of the gentamicin congeners (gentamicin C1, C1a, C2 and C2a) was
very small across the range of conditions studied. The largest variation
seen in rods stored under high humidity and oxidation. The proportion
of gentamicin C2 changed by 5% (Figs. 3B and 3C). A comparison of the
change in composition of the minor impurities using LC–MS revealed
that the biggest change was seen in the amounts of gentamine C1
formed after storage (Fig. 6). Under conditions of low humidity both
GS coated rods and those coated with GS and PLGA showed a
signiﬁcant increase in levels of gentamine C1 detected. This eﬀect
was even more pronounced when rods subjected to highly oxidizing
conditions were examined. In addition, an increase in the other
gentamine impurities (gentamines C1a and C2) was also evident.
4. Conclusions
GS and GS/PLGA coated hydroxyapatite rods were subjected to
Fig. 5. (A) The eﬀect of γ-irradiation on the GS composition (measured by HPLC–ELSD)
and (B) the relative levels of common GS impurities (measured by LC–MS). Control:
control extraction, GR: GS coated rod, GRP: GS and PLGA coated rod.
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high and low temperature, humidity, oxidation and light exposure
environments over a period of 30 days. LC–ELSD and LC–MS analyses
of extracts from GS coated rods indicated that they were stable under
storage at 60 °C and also to light exposure. High humidity had a
minimal eﬀect on the composition of GS. In contrast, rods coated with
both GS and PLGA were more sensitive to storage conditions with
compositional changes being detected after storage at 60 °C, 75% RH
or exposure to light. Storage of both GS and GS/PLGA coated rods in
an oxidizing atmosphere resulted in signiﬁcant changes to the genta-
micin composition but no unexpected impurities were detected by LC–
MS. The major degradants detected were the gentamines arising from
degradation of the corresponding gentamicin C components. Finally,
the eﬀect of γ-irradiation on the gentamicin composition of GS and GS/
PLGA coated rods was also investigated and found to have no
signiﬁcant eﬀect. Based on this preliminary study, investigation of
long-term storage of the GS and GS/PLGA coated rods under appro-
priately controlled conditions (namely protected from light, avoiding
high temperature and exposure to air) is warranted.
In conclusion, a systematic approach has been developed to
investigate the chemical stability of drug coatings applied to medical
implant devices. This methodology was applied to the study of
hydroxyapatite rods coated with gentamicin to determine the degra-
dative behavior of gentamicin on a device surface.
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